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Abstract. Recently, 3-dimensional supramolecular coordination complexes of the metallacage type have been 
shown to hold promise as drug delivery systems for different cytotoxic agents, including the anticancer drug 
cisplatin. However, so far only limited information is available on their uptake and sub-cellular localisation in 
cancer cells. With the aim of understanding the fate of metallacages in cells by fluorescence microscopy, three 
fluorescent Pd2L4 metallacages were designed and synthesised by self-assembly of two types of bispyridyl 
ligands (L), exo-functionalised with boron dipyrromethene (BODIPY) moieties, with Pd(II) ions. The cages 
show high quantum yields and are moderately stable in the presence of physiologically relevant concentration 
of glutathione. Furthermore, the cages are able to encapsulate the anticancer drug cisplatin, as demonstrated 
by NMR spectroscopy. Preliminary cytotoxicity studies in a small panel of human cancer cells showed that the 
metallacages are scarcely toxic in vitro. The marked fluorescence due to BODIPY allowed us to visualise the 
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cages’ uptake and sub-cellular localisation inside melanoma cells using fluorescence microscopy, highlighting 
uptake via active transport mechanisms and accumulation in cytoplasmic vesicles.  
Keywords: supramolecular coordination complexes; metallacages; cisplatin; fluorescence microscopy; 
cancer. 
Introduction 
Supramolecular coordination complexes (SCCs) have been attracting increasing attention over the 
past few decades due to their several potential applications in different areas, including sensing, 
molecular recognition and catalysis.[1] More recently, SCCs have been designed for biomedical 
applications, including as anticancer drugs or as novel drug delivery systems.[2,3] The latter 
application still needs validation, but the high versatility of these supramolecular systems holds great 
promise. Overall, SCCs as drug delivery systems can be based on i) both encapsulation of a drug, 
driven by hydrophobic interactions between the cargo drug molecule and the host cavity, and non-
covalent interactions within the host cavity, as well as ii) covalent bonding of a prodrug species to the 
SCC architecture.[2]  
 In this context, inspired by the work of Therrien,[4,5] Crowley[6] and others,[2,7] we have explored 
the potential of metallacages - of the Pd2L4 type (L = 3,5-bis(3-ethynylpyridine)phenyl) - as novel drug 
delivery systems for the anticancer drug cisplatin.[8] Thus, we exploited the host-guest properties of 
the cages to encapsulate cisplatin and protect it from speciation. NMR spectroscopy and X-ray 
diffraction studies showed encapsulation of two cisplatin molecules per cage unit.[8] Of note, the 
selected metallacages are non-toxic in both cells and tissues, making them suitable for application as 
drug delivery vectors.[8]  
 More recently, we developed a method to bioconjugate Pd2L4 cages to peptides based on amide 
bond formation between the cage-ligands and amino or carboxylic acid groups in the peptide chain.[9] 
Thus, we selected peptidic ligands for targeting of integrins overexpressed in cancer cells.[10] The 
results showed that cisplatin encapsulated in the targeted cages had a two-fold increase in cytotoxic 
potency in melanoma cells after 24 h incubation.[10] Moreover, reduced toxicity of cisplatin 
encapsulated in integrin-targeted metallacages was also demonstrated in healthy tissues ex vivo.[10]  
 While the Pd2L4 cages are very promising for cisplatin delivery, their mechanism of cancer cell 
uptake is still not fully understood; this prevents their optimisation as targeted drug vectors. In order to 
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study the cages intracellular accumulation and sub-cellular localisation, fluorescence microscopy is 
the preferred technique, allowing analysis with intact cells while avoiding complex cell fractionation 
steps which may lead to reduced analyte recovery, and lack of reproducibility.   
 Although the ligands used to build the cages are highly luminescent, upon self-assembly quenching 
of their fluorescence is normally observed due to the so-called ‘heavy metal’ effect.[8] While the 
emissive properties of metallacages have been discussed,[11,12] examples of highly emissive Pd2L4 
cages are rare. Previously, we have reported on a number of Pd2L4 cages exo-functionalised with 
luminescent moieties, including anthracenyl groups[13] and Ru(II) polypyridyl ligands.[14] However, 
while the former did not display sufficient luminescence due to the lowered probability of π -π* 
excitation upon conjugation of the fluorophore to the ligand scaffold,[13] the latter achieved strong 
emission only upon excitation in the UV region,[14] which is not ideal for conventional microscopy 
analysis. 
 Here, we developed a new family of Pd2L4 cages exo-functionalised with highly fluorescent boron 
dipyrromethene (BODIPY) scaffolds. BODIPYs are a family of fluorescent dyes used for many 
applications such as solar cells,[15] imaging[16] and photodynamic therapy.[17] The characteristic 
fluorescence of the BODIPY moieties conjugated to the metallacages enables their intracellular 
visualisation using fluorescence microscopy. Other supramolecular structures, such as Ru(II) metalla-
rectangles, containing BODIPY ligands have been reported, but these were used as cytotoxic agent 
per se and not as drug delivery systems.[18,19]  
 Three new BODIPY-cages, featuring either an amide bond or a 1,2,3-triazole ring to tether the cage 
bispyridyl scaffold to the fluorophore, were synthesised by self-assembly and characterised by various 
methods, including NMR spectroscopy, high-resolution mass spectrometry and fluorescence 
spectroscopy. Furthermore, the stability of the cages in aqueous solution was investigated using UV-
Visible spectroscopy, while their interactions with physiologically relevant concentrations of glutathione 
(GSH), which is a common intracellular antioxidant with an increased level in cancer cells, were 
investigated by 1H NMR spectroscopy. The encapsulation of cisplatin was also studied by both 1H and 
195Pt NMR spectroscopy. The antiproliferative effects of the cages were assessed in the human 
malignant melanoma A375 cell line to evaluate possible cytotoxic effects, while the uptake and sub-
cellular distribution of selected metallacages were studied by fluorescence wide-field and confocal 
microscopy. 
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Results and discussion 
Synthesis 
The synthesis of highly luminescent Pd2L4 metallacages was achieved by the conjugation of the 
BODIPY fluorophore to the bispyridyl ligand scaffold. This could be formed either via amide bond 
formation or by copper catalysed azide-alkynyl cycloaddition (CuAAC) reaction depending on the 
functional groups of the fluorophore and ligand. Thus, an amine exo-functionalised ligand was 
synthesised via Sonogashira cross coupling between dibromoaniline and two equivalents of 3-ethynyl 
pyridine, according to a previously reported procedure,[14] to afford the amine functionalised ligand 
(L1). Afterwards, L1 could be converted to the corresponding azide exo-functionalised ligand by in situ 
substitution of the amine for a reactive nitro group, followed by substitution of the nitro group to afford 
the corresponding azide functionalised ligand (L2) (Scheme S1). 
 The BODIPY fluorophores were synthesised by adapting previously reported procedures.[20–22] 
In details, 3-ethyl-2,4-methylpyrrole was stirred at room temperature in dichloromethane (DCM) with 
the appropriate para-functionalised benzaldehyde in the presence of catalytic amounts of 
trifluoroacetic acid (TFA) to afford the organic scaffold of the BODIPY fluorophore. The functional 
group of the final BODIPY could be easily modified by the choice of the para- functional group of the 
benzaldehyde starting material. Coordination of the BF2 moiety to the organic scaffold was 
accomplished by first deprotonating the pyrrole functional groups using 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ), before introducing boron trifluoride diethyl etherate in the presence of 
triethylamine to produce the carboxylic acid functionalised BODIPY (B1) and alkynyl functionalised 
BODIPY (B2). 
 L1 was coupled to B1 via classical amide bond formation to afford LB1 (Scheme S2). L1, B1, 1-
chloro-2-methylpyridinium iodide (CMPI), and 4-dimethylaminopyridine (DMAP) were stirred in 
dimethylformamide (DMF) at 130 °C for 16h, before purification via chromatography on silica to give 
BODIPY functionalised ligand LB1. L2 was coupled to B2 via CuAAC “click” chemistry to achieve LB2 
(Scheme S3). In detail, L2 and B2 were dissolved in DCM and the solution diluted with a solution of 
methanol:water (3:1). The reducing agent, sodium ascorbate, was made in situ by dissolving L-(+)-
ascorbic acid with sodium hydroxide in water. To this mixture, CuSO4 was added and the resulting 
aqueous solution was added to the organic solution containing L2 and B2 and stirred at room 
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temperature for 5 h. The reaction was quenched using ammonium acetate, before the solution was 
extracted with DCM and purified via chromatography on silica to afford the BODIPY functionalised 
ligand LB2. 
 Finally, the BODIPY exo-functionalised Pd2L4 metallacages were formed via self-assembly by 
mixing 4 equiv. of ligand LB1 or LB2 with 2 equiv. of Pd2+ at room temperature in DMSO to afford 
cage C1.X (X = BF4-, NO3-) or C2.NO3, respectively (Scheme 1). The counterion could be varied using 
the appropriate Pd2+ salt (see supplementary material for details). All the ligand precursors and cages 
were characterised by various methods, including 1H, 13C, 11B and 19F NMR spectroscopy and high-
resolution mass spectrometry. The obtained results indicate that discreet supramolecular complexes 
of the formula Pd2L4 form via self-assembly under these conditions. Representative 1H NMR spectra 
for ligand LB1 and cage are compared in Figure 1 and show that, upon cage formation, significant 
downfield chemical shifts of protons peaks Ha and Hb, indicative of coordination to the Pd(II) ions, can 
be observed in accordance with previously reported studies.[8,10,11] Furthermore, the ligands and 
cages were studied for their emission properties, and the respective quantum yields (Table 1) 
calculated as described in the experimental section. Of note, at variance with previously reported 
metallacages exo-functionalised with different fluorophores,[13] the BODIPY-cages maintained 
excellent quantum yield values. Of note, the BODIPY-cages have been designed with a scaffold 
featuring slightly longer ‘linkers’ between the fluorogenic moiety and the ligand δ with respect to 
previously reported cages,[13] which may reduce the conjugation between the two systems preventing 
the quenching of the fluorescence upon self-assembly. 
 
UV-Visible spectrophotometry stability studies 
The stability of the metallacages C1.BF4, C1.NO3, and C2.NO3 in water and phosphate buffered saline 
(PBS, pH 7.4) was studied by UV-Visible spectrophotometry. As shown in Figures S22-S24, the 
absorption spectra of the three cages, featuring two main bands at ca. 300 and 530 nm, were 
completely stable in water over 24 h. Metallacages C1.BF4 and C1.NO3 were also sufficiently stable 
in PBS solution (pH 7.4) although marked reduction of the two absorption bands was observed at 4 h 
incubation and continued over the 24 h period. While over 24 h a precipitate was formed in solution, 
shaking of the cuvette partly restored the original absorption spectrum (see Fig. S22-S23). It should 
be noted that the solubility of metallacages is determined by a number of factors, including the 
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properties of the main ligand scaffolds, the metal ion, as well as the type of counter ion balancing the 
cage overall positive charge. In such a complex interplay of elements it is difficult to establish what 
causes cage precipitation and/or instability in solution. Furthermore, it should be noted that the 
BODIPY-ligand system also presents some issues of solubility/stability in buffered solution, most 
probably due to the hydrolysis of the B-F moiety. Certainly, from the obtained UV-visible data, the 
presence of other anions in the buffer (pH 7.4) favours the observed spectra changes, and formation 
of a precipitate in solution.  
The spectrum of metallacage C2.NO3 in PBS solution underwent even more pronounced reduction of 
intensity after only 2 h (Figure S24), and any attempt to re-dissolve the precipitate would not restore 
the original signal intensity. Therefore, Pd2L4 metallacage C2.NO3 was not used for further biological 
characterisation due to its poor solubility in physiological media. The enhanced instability of the 
C2.NO3 cage with respect to the BF4- derivatives may be attributed to possible increased encapsulation 
of the nitrate ion into the cavity, as well as to its higher coordinating affinity towards the Pd(II) centres.  
 
Interactions with GSH 
Afterwards, we examined the stability of the cages in the presence of physiologically relevant concentration of 
glutathione (GSH, 2 mM) by NMR spectroscopy. Therefore, GSH was added to a solution of cage C1.BF4 in 
DMSO-d6:D2O (9:1) and 1H NMR spectra were recorded over time over 18 h (Figure 2). The obtained results 
show that, upon addition of GSH, the metallacage disassembles into its precursors, as shown by the 
appearance of the peaks characteristic of the ligand LB1. However, part of the cage remains stable over time 
(ca. 30%, calculated by comparing the integral value of peak Hb of the metallacage to the peak of Hb of the 
ligand), and only further addition of excess GSH allows complete disintegration of C1.BF4 (Figure 2). This 
observation supports the hypothesis that the cage can partly remain intact in the cytosol. 
 
Encapsulation of cisplatin  
1H NMR spectroscopy  
We have previously demonstrated the encapsulation of cisplatin within Pd2L4 metallacages via 1H NMR 
spectroscopy in DMF-d7.[10,23] Similarly, metallacages C1.BF4 and C1.NO3 were dissolved in DMF-
d7 and the respective 1H NMR spectra were recorded. Afterward, two equiv. of cisplatin were added to 
 
  
7 
the deuterated solution and a second 1H NMR spectrum was recorded and compared with the previous 
one. The chemical shifts of all the proton signals were then compared between the spectra of C1.BF4 
and encapsulated (cisplatin)2C1.BF4 (Figure S25) and between C1.NO3 and (cisplatin)2C1.NO3 
(Figure S26). In both cases, the same three proton signals - namely, the two signals corresponding to 
the protons facing the internal cavity (Ha and He), as well as the signal of the exo-facing proton (Hb), 
which is alpha to the coordinating nitrogen of the ligand - were observed to undergo chemical shifts 
changes due to cisplatin encapsulation, as previously reported.[23]  
Specifically, the signals of the cavity facing protons, Ha and He, for (cisplatin)2C1.BF4 both underwent 
a slight downfield shift (+0.03 ppm and +0.08 ppm, respectively) when compared to C1.BF4 (Figure 
S25). Furthermore, for both cages, the signal of the central cavity facing proton, He, was significantly 
broadened, suggesting intermolecular interactions between the host Pd2L4 metallacage and the 
cisplatin guest molecule.  
 However, upon comparison of the 1H NMR spectra of (cisplatin)2C1.NO3 and C1.NO3, the cavity 
facing proton (Ha and He) signals undergo a very small upfield shift (-0.02 ppm in both cases). We 
have previously reported a similar observation between Pd2L4 type metallacages which differ only in 
their counterions (either NO3- or BF4-).[23] This finding are in line with previous studies by Crowley and 
co-workers,[24] according to which while the NO3- counterion can be encapsulated within the Pd2L4 
metallacage, BF4- is not. Therefore, the cavity facing protons of C1.NO3 are in close proximity to the 
negatively charged NO3-, and thus, their signals are shifted further downfield compared to C1.BF4, in 
which the cavity is occupied by neutral solvent molecules. Upon encapsulation of cisplatin to C1.NO3, 
the counterion is exchanged for cisplatin as the guest and the signals of the cavity facing protons 
undergo a slight upfield shift. In the case of C1.BF4, the counterion is not encapsulated within the 
cavity, and so the downfield shift of the signals of the cavity facing protons can be attributed to the 
evacuation of solvent molecules, and the occupation of the cavity with cisplatin. 
 
195Pt NMR spectroscopy 
In order to further characterise the encapsulation of cisplatin within the metallacage C1.BF4, 195Pt NMR 
spectroscopy was applied. Initially, one equiv. of cisplatin was dissolved in DMF (0.5 mL) and this 
solution was added to the NMR tube with a capillary insert filled with DMF-d7 and a spectrum was 
recorded (Figure 3, top spectrum). To this solution, one equiv. of metallacage was added and a second 
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195Pt spectrum was recorded in order to obtain a 1:1 cisplatin:cage stoichiometry (Figure 3, bottom 
spectrum). Finally, a second equiv. of cisplatin was added to the metallacage containing solution and 
a third spectrum was recorded (Figure 3, middle spectrum). Comparison of the spectra showed that 
upon addition of metallacage C1.BF4 an upfield shift (  [ppm] = -1.9) was observed for the 195Pt peak 
of cisplatin at -2080.2 ppm. This shift is indicative of the fact that the 195Pt nucleus is experiencing 
more electronic shielding due to encapsulation within the metallacage cavity. The shift is fully resolved 
for the sample containing two equiv. of cisplatin, in accordance with previously reported studies.[23]  
 
Antiproliferative effects 
The antiproliferative effects of cisplatin encapsulated in cage C1.BF4 were studied against the human 
malignant melanoma A375 cell line after 24 h incubation, when the free metallodrug is known to be poorly 
active. This also allowed for microscopy analysis at suitable metallodrug concentration levels (see 
Experimental for details). The resulting EC50 (concentration of a drug that gives half-maximal response) values 
are reported in Table 2 and show that the cage and respective ligand precursor are non-toxic at the highest 
tested concentration (EC50 > 50 M). We also repeated the study with encapsulated cisplatin 
[(cisplatin)2C1.BF4]. As these cage systems are not specifically targeted to human cancer cells, we did not 
expect to observe the same increase in the anticancer potency of cisplatin as observed for the previously 
published integrin-targeted metallacages.[10] In fact, the encapsulated cisplatin did not show any significant 
variation of the antiproliferative activity with respect to free cisplatin (Table 2). 
 
Uptake and cellular localisation studies 
The detection of the BODIPY-cages C1.BF4 and C1.NO3 and their respective ligand precursor LB1 was 
achieved by fluorescence microscopy. The cages/ligand (5 M) were incubated with A375 cells for 2 h at 37 
°C, fixed and visualised by confocal fluorescence microscopy. LB1 alone was observed in punctate structures 
and as diffuse labelling (Figure 4). Both cages C1.NO3 and C1.BF4 were internalised independently of the 
respective counter ions, to again label vesicular structures that were particularly prominent for C1.BF4, with 
C1.NO3 enriched in a juxtanuclear region. Z-section analysis of cell treated with C1.BF4 confirmed the 
intracellular location of these compounds as opposed to aggregation and accumulation on the cell surface 
(Figure S27A). The results also show that the cage does not reach the cell nuclei to any significant extent. 
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Similar fluorescence profiles were observed in LB1 and B1 incubated cells (Figures 4 and S27B). Currently, it 
is impossible to determine if the cages remain intact or are disintegrated once internalised. The specific sub-
cellular distribution observed for these particular BODIPY-cages is unexpected as other studies with BODIPY-
containing metal-based scaffolds showed that they internalise into more non-descript diffuse structures,[25] 
rather than selectively accumulating in vesicles as particularly observed for C1.BF4 .  
Finally, in order to establish if the mechanisms of cage uptake in cancer cells is active or relies on passive 
diffusion, we performed the same experiments at either 37 or 4 °C. The results are shown in Figure S28 and 
demonstrate that no fluorescence signal can be detected in cells incubated at 4 °C, thus, excluding passive, 
energy independent diffusion of the cages (and ligand) through the plasma membrane and pointing towards 
endocytosis as the mechanism of uptake. 
 
Conclusions 
We have reported here on the synthesis and characterisation of three new Pd2L4 metallacages 
featuring 3,5-bis(3-ethynylpyridine)phenyl ligands exo-functionalised with BODIPY units. The cages 
showed remarkable luminescent properties with quantum yields of 50-70% and excitation wavelength 
in the visible region (ca. 540 nm), which make them suitable for imaging in cells. The cages were 
studied for their stability in aqueous solution by UV-visible spectroscopy, and for their reactivity in the 
presence of physiologically relevant concentration of GSH. Of note, cage C1.NO3 dissociated only 
partially in the presence of this intracellular nucleophile. Moreover, the encapsulation properties of the 
anticancer drug cisplatin in the metallacages were studied by 1H and 195Pt NMR spectroscopy. The 
obtained results showed that up to 2 equiv. of cisplatin can be encapsulated in a cage molecule. The 
two cages in which the BODIPY moiety is linked to the cage scaffold by amide bond (C1.BF4 and 
C1.NO3) were then tested against human A375 cancer cells showing no cytotoxic effects, which make 
them suitable for applications as drug delivery systems. 
Moreover, the uptake and sub-cellular localisation of the cages in cancer cells was observed by both 
wide field and confocal fluorescence microscopy, revealing that cages are subjected to active 
endocytic transport, prior to accumulation in intracellular vesicles. 
In future studies, it will be particularly interesting to identify the nature of the C1.BF4 labelled structures to 
determine if they are early endosomes, late endosomes/lysosomes or other structures such as melanosomes. 
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It will also be important to determine how this localisation of the cage affects the cisplatin release profile. 
Furthermore, preliminary Isothermal Titration calorimetry (ITC) data also show that cisplatin can be 
encapsulated in Pd2L4 metallacages in aqueous solution and in physiologically relevant concentrations. 
However, further studies are necessary to exclude cisplatin release prior uptake of the host-guest system.  
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Figures and Tables 
 
Scheme 1 - Synthesis of the Pd2L4 metallacages exo-functionalised with BODIPY fluorophores reported in this 
study. 
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Figure 1 – Stacked 1H NMR spectra zoomed into the aromatic region showing: Top: ligand LB1 
(DMSO-d6). Bottom: Metallacage C1.BF4 (DMSO-d6). Self-assembly of the metallacages could be 
followed by the large downfield shift of peaks Ha and Hb indicative of coordination to the Pd(II) ions. 
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Figure 2. Stacked 1H NMR spectra of ligand LB1 (top) and of the corresponding metallacage C1.BF4 (second 
trace from top) in 9:1 ratio of DMSO-d6: D2O, in the presence of 2 mM glutathione over time. A further addition 
of excess GSH was performed after 18 h to achieve complete cage dissociation (bottom spectrum). 
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Figure 3 - Stacked 195Pt NεR spectra in DεF of: (top) cisplatin (  [ppm] = -2080.2); (middle) C1.BF4 + 2 equiv. 
of cisplatin (  [ppm] = -2082.1); (bottom) C1.BF4 + 1 equiv. of cisplatin (  [ppm] = -2082.1). 
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Figure 4 - Confocal Laser Scanning Microscopy (CLSM) Images of fixed human A375 melanoma cells pre-
treated with ligand LB1 or cages C1.BF4 and C1.NO3 for 2 h at 37 °C.  Scale bar represents 20 µm. Data 
represents maximum projection images. 
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Table 1 - Photophysical data obtained by UV-Visible spectrophotometry and fluorescence spectroscopy for 
the BODIPY fluorophores (B1 and B2), BODIPY functionalised bispyridyl ligands (LB1 and LB2), and the 
fluorescent Pd2L4 metallacages (C1.NO3, C1.BF4, and C2.NO3). 
Compound 
λmax (Abs)  
[nm] 
max 
[M-1 cm-1] λmax (Em) [nm] ϕF [%] 
B1 525 53 300 544 72 
B2 525 72 700 543 75 
LB1 290, 525 66 600 544 76 
LB2 525 50 000 543 74 
C1.NO3 291, 527 42 100 544 50 
C1.BF4 291, 525 111 000 544 64 
C2.NO3 291, 525 160 000 543 70 
 
 
 
 
 
Table 2 - Antiproliferative activity (EC50 values) of different cage and cage:cisplatin (1:2) formulations against 
human A375 cells after 24 h incubation, compared to cisplatin. 
Compound EC50 (M)a 
LB1 > 50 
C1.NO3 > 50 
C1.BF4 > 50 
(cisplatin)2C1.BF4b 29 ± 2 
cisplatin 33.9 ± 2.9 
a Data is presented as mean ± SEM of at least three independent experiments. 
b The EC50 is calculated with respect to the concentration of free cisplatin. 
 
 
 
